The Limitations of Traditional Approaches
Using staging systems alone may miss patients with aggressive tumor biology. Listen in, to learn how DecisionDx-Melanoma addresses these limitations by improving prognostic accuracy.
A Life Changing Prognosis of Uveal Melanoma: Kevin’s Story
After being diagnosed with uveal (or ocular) melanoma, Kevin was directed to explore the benefits and indications of Castle Biosciences' DecisionDx®-UM gene expression profile (GEP) test, which predicts a patient’s risk based upon their tumor’s own unique biology. The findings of the test, Kevin says, "were of huge importance to myself and my family. They put me at rest and we could all move on. The Castle uveal melanoma prognostic platform can truly be life-changing."